



{ قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلِمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ
الْحَكِيمُ }

صدق الله العظيم
سورة البقرة
آية رقم (32)

Dedication

To the soul of my great father

...

To my lovely mother for
embracing me with an ever-
lasting emotion.. and kindness

...To my lovely family

To my friends ... and my
... colleagues

To everyone from whom I
...learned

Amal

DECLARATION

This research was carried out by the undersigned at the Sudan University Science & Technology, during the period 2004-2005 and was not submitted for any degree before.

Signature:

Amal Rajab Abd-El Baset

Dr. Mohammed Abd-Elraheem

Acknowledgement

I am extremely grateful to my teacher and supervisor **Dr. Mohamed Abed Elraheem**, the coordinator of post graduate studies, for his confidence in delivery this subject to me to work on. My deepest gratitude would be expressed for him to his advice, encouragement and meticulous supervision.

My appreciation to *Dr. Muna Mohamed Abed Elkarim* a physician in Port Sudan Teaching Hospital for her grateful advice.

I would like to extend my thanks to my friend *Dr. Asma Mohamed Ahmed El Bedlaa* for her kind help and valuable advice.

I would like to express special appreciations to my colleagues in Elshahid *Dr. Bakri Yassin*. Center Lab staff, and Seaport Hospital, lab staff and health insurance lab staff for their help in sample collection.

My great thanks to *Miss. Shereen Yousif* and *Husham Badereldin* for their patience in the long hours they spent in typing and *El-Farazdug Omer Hamed* for his grateful help in analyzing the data.

I extent my great thanks to my relatives and friends who supported me, with great real feelings, always praying for me.

I would like to extend my thanks to all authors listed in the reference list for literatures that I had reviewed.

It is a pleasure to acknowledge patients and controls that were enrolled in this study, without whom this work would be impossible.

ABBREVIATIONS

ADH	Anti Diuretic Hormone
ADP	Adenosine Diphosphate
AMP	Adenosine Monophosphate
ATP	Adenosine Triphosphate
DCCT	Diabetes Complication Control Trial
DDAVP	Deamino-8-D-Arginine Vasopressin
DKA	Diabetic Keto Acidosis
DM	Diabetes Mellitus
DNA	Deoxyribo Nucleic Acid
ESR	Erythrocyte Sedimentation Rate
FFA	Free Fatty Acid
GFR	Glomerular Filtration Rate
GMP	Guanosine Monophosphate
H⁺	Hydrogen Ion
IDDM	Insulin Dependent Diabetes Mellitus
IMP	Inosine Monophosphate
LDL	Low Density Lipoproteins
NIDDM	Non-Insulin Dependent Diabetes Mellitus
RNA	Ribonucleic Acid
SD	Standard deviation
TCA	Tricarboxylic Acid Cycle
TNFα	Tumour Necrosis Factor
VLDL	Very Low Density Lipoproteins
WHO	World Health Organization

ABSTRACT

A prospective study was conducted during the period, April 2004 to April 2005.

Hyperuricaemia and diabetes mellitus (D.M) are interrelated diseases and frequently concomitant.

In this study a total of (200) subjects were examined for serum uric acid level.

Hundred (100) subjects were known diabetics. Twenty-one of them were type I (IDDM) and seventy-nine were type II (NIDDM). Hundred non-diabetic patients were chosen as control group.

The diabetic group (n= 100) (Male= 50, Female= 50), were divided into sub groups according to sex, age, duration of diabetes, modes of treatment diet and glycaemic control. A sample from each subject was analyzed for serum uric acid and random blood glucose. The results were statistically analyzed.

All patients are suffering from hyperglycaemia. There were significant differences between two means of diabetic patients and control subjects $320\text{mg/dl} \pm 16.2\text{ mg/dl}$, $110\text{mg/dl} \pm 13.0\text{ mg/dl}$ and probability $P. < 0.05$ respectively.

The results obtained showed that there was a highly significant difference in the mean of serum uric acid (mg/dl) for the diabetic patients ($7.293\text{ mg/dl} \pm 0.6332\text{ mg/dl}$) and the mean of serum uric acid (mg/dl) for the control group ($4.902\text{ mg/dl} \pm 0.1109\text{ mg/dl}$) $P.$ value < 0.05 .

Forty five percent (45%) in both types of diabetes were suffering hyperuricaemia while (55%) in both types were not hyperuricaemic.

No significant differences were found among gender.

Types of diet, poor glycaemic control and old age are found to be risk factors for hyperuricaemia particularly in type II DM.

In this study 10 percent from all diabetic patients were found to be typical gouty patients most of them from type II DM.

Finally this study showed that the hyperuricaemia and gout are uncommon before the age of 30 years.

ملخص الأطروحة

مرض السكر ومرض النقرس (داء الملوك) متلازمان ووجودهما معاً يشكل عيناً كبيراً على المرضى.

أجريت هذه الدراسة التوقيعية خلال الفترة من أبريل 2004م وحتى أبريل 2005م وفيها تم تحليل مستوى حمض البيوريك في مصل الدم الألخوذ من 200 فرداً تم تقسيمهم إلى مجموعتين المجموعة الأولى وتضم 100 فرداً من المصابين بداء السكري بنوعيه ، النوع الأول يضم 21 مريضاً والنوع الثاني ويضم 79 مريضاً. المجموعة الثانية وتضم 100 فرداً من غير المصابين بداء السكري للمقارنة (مجموعة التحكم).

تم تقسيم المجموعة الأولى إلى مجموعات صغيرة ، وذلك اعتماداً على نوع المريض (ذكر أو أنثى) ، عمر المريض ، عمر الاصابة بداء السكري ، نوع العلاج ، النظام الغذائي المتبعة ، التحكم في المرض والكشف الدوري.

تمأخذ عينة من كل فرد لتحديد وقياس مستوى حمض البيوريك ومستوى السكر في مصل الدم ، وقد تم تحليل جميع النتائج إحصائياً. وجد أن جميع المرضى يعانون من ارتفاع في مستوى السكر (فرط السكر) مقارنة بمجموعة التحكم كما يوضح ذلك الفرق في المستوى الوسطي لكليهما على التوالي 16.2 ± 320 ملغم/ ديسيليتر ، 13.0 ± 110 ملغم / ديسيليتر.

لوحظ أن هناك فرق ذو دلالة معنوية إحصائية بالنسبة لارتفاع مستوى حمض البيوريك عند المجموعة الأولى أي المرضى المصابين بداء السكري حيث كانت الزيادة في المستوى الوسطي لحمض البيوريك : 7.293 ± 0.6332 ملغم / ديسيليتر مقارنة بغير المصابين أو المجموعة الثانية. حيث كانت الزيادة في المستوى الوسطي 4.902 ± 0.1109 ملغم / ديسيليتر باحتمال احصائي أقل من 0.05

أثبتت الدراسة أن نسبة انتشار مرض النقرس وارتفاع معدل حمض الاليوريك في الدم عند المرضى المصابين بالسكري 45%. و 55% من المرضى لا يعانون من مرض النقرس.

أثبتت الدراسة أنه ليس هنالك فرق بين الجنسين (الإناث أو الذكور) من حيث الإصابة بداء النقرس.

النظام الغذائي غير المتوازن ، عدم تنظيم السكر في الدم ، وتقديم العمر عوامل مساعدة لحدوث ارتفاع مستوى حمض الاليوريك في الدم وبالتالي الإصابة بداء النقرس عند المرضى بالنوع الثاني من السكري على الأخص.

أثبتت الدراسة أن 10% من مرضى السكر مصابون بالنقرس بأعراضه المعروفة ونسبة الاليوريك عندهم أكثر من 10 ملغم لكل 100 مل و معظمهم من مرضى السكري من النوع الثاني.

وأخيراً أثبتت الدراسة أن الإصابة بداء النقرس ليس شائعة عند مرضى السكري الذين تقل أعمارهم عن 30 سنة.

LIST OF TABLES

Table 1- 1:	Foods that are high in purines include	40
Table 1- 2:	Classification of hyperuricaemia	44
Table 3- 1:	Duration of diabetes in diabetic patients in study group	62
Table 3- 2:	Glycaemic control in diabetic patients	63
Table 3- 3:	Distribution of diabetic patients according to diet intake	64
Table 3- 4:	Type of treatment in diabetic patients	65
Table 3- 5:	Frequency of gout symptoms in diabetic gouty patients	66
Table 3- 6:	Random blood glucose concentration in both diabetic and control subjects	67
Table 3- 7:	Uric acid concentration in diabetic patients and control	68
Table 3- 8:	Uric acid concentration in diabetic males and Females	69
Table 3- 9:	Prevalence of gout in diabetic patients in both types of D.M (uric acid conc. > 10 mg/dL)	70
Table 3- 10:	Prevalence of hyperuricaemia in diabetic patients according to sex	71
Table 3- 11:	Distribution of hyperuricaemia in type I diabetes mellitus according to the age group	72
Table 3- 12:	Distribution of hyperuricaemia in type II diabetes mellitus according to the age group	73

Table 3-13:	Distribution of diabetic patients in relation to the age group	74
--------------------	--	----

LIST OF FIGURES

Figure 1-1:	Purine Ring	25
Figure 1-2:	Biosyntheses of purine	25
Figure 1-3:	Purine biosyntheses and uric acid information	27
Figure 1-4:	Conversion of uric acid to allantoin	34
Figure 1-5:	Phosphoribosylation of hypoxanthine and guanine to form IMP and GMP respectively	34
Figure 1-6:	Pathogenesis of acute gouty arthritis	49
Figure 3-1:	Duration of diabetes in diabetic patients in study group	62
Figure 3-2:	Glycaemic control in diabetic patients	63
Figure 3-3:	Distribution of diabetic patients according to diet intake	64
Figure 3-4:	Type of treatment in diabetic patients	65
Figure 3-5:	Frequency of gout symptoms in diabetic gouty patients	66
Figure 3-6:	Random blood glucose concentration in both diabetic and control subjects	67
Figure 3-7:	Uric acid concentration in diabetic patients and control	68
Figure 3-8:	Uric acid concentration in diabetic males and Females	69
Figure 3-13:	Distribution of diabetic patients in relation to the age group	74